Navigation Links
Pharmasset to Present at the UBS Global Life Sciences Conference
Date:9/17/2010

PRINCETON, N.J., Sept 17 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the UBS Global Life Sciences Conference to be held September 20-22, 2010 at the Grand Hyatt, New York, NY. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the UBS conference on Monday, September 20, 2010 at 9:30 AM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys(R) plus Copegus(R) and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently initiated 12 weeks of dosing in a Phase 2b study, and PSI-938, an unpartnered guanosine nucleotide analog in a Phase 1 study. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development. Racivir, for the treatment of HIV, has completed a Phase 2 clinical study.

Pegasys(R) and Copegus(R) are registered trademarks of Roche. ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice:

+1 (609) 613-4181Forward-Looking Statements Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2009 and our Quarterly Reports on Form 10-Q for the periods ended December 31, 2009, March 31, 2010 and June 30, 2010 filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
2. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
3. Pharmasset Reports Fiscal Year End 2009 Financial Results
4. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
5. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
6. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
7. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
8. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
9. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
10. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
11. Pharmasset Reports Fiscal Year End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) ... 2017 financial results before the market opens on Thursday, ... United Therapeutics will host a teleconference on Thursday, July ... is accessible by dialing 1-877-351-5881, with international callers dialing ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 2017 , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been ... (SLMBNI), part of Saint Luke’s Health System . Dr. Upadhyaya has served in ... M.Sc., FAANS joins Stanley P. Fisher, M.D., who has served as medical ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Cosmetic Town, ... doctors and the cosmetic surgeries they perform on a daily basis. , The ... cosmetic surgery procedures they specialize in at their practices. , When asked about ...
(Date:7/24/2017)... Hagerstown, MD (PRWEB) , ... July 24, 2017 ... ... County Public Schools (MCPS) have partnered together for a unique opportunity that helps high ... their mission of “Removing Barriers, Creating Opportunities.” Horizon Goodwill will host over ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... $1,000 total in scholarship awards to be awarded annually to and divided between ... an interest in bringing awareness to Amazonian plant medicine. To apply for the ...
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
Breaking Medicine News(10 mins):